Cite
HARVARD Citation
Sigurgeirsson, B. et al. (2022). Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of dermatological treatment. pp. 1718-1726. [Online].